BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth
8 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
5 independently detected trends connected to this subject, with the latest coverage first.
This hub groups 5 separate news trends connected to Bristol Myers, spanning August 26, 2026 through October 12, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 39 article observations and 39 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
8 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Bristol Myers' blood cancer cell therapy achieves key milestone in mid-stage trial
Novartis and Bristol Myers have halted autoimmune CAR-T trials after three patient deaths.
Novartis and Bristol Myers have paused CAR-T trials after patient deaths, raising safety concerns in the biopharma industry.
Bristol Myers Squibb ends blood‑cancer deal, prompting Cellares to cut 100 jobs and reorganize.